MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 575939 | Name: Gonadorelin diacetate hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gonadorelin diacetate hydrate is a decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, Luteinizing Hormone and Follicle Stimulation Hormone. GnRH is produced by neurons in the septum preoptic area of the hypothalamus and released into the pituitary portal blood, leading to stimulation of gonadotrophs in the anterior pituitary gland.

Chemical Structure

Gonadorelin diacetate hydrate
Gonadorelin diacetate hydrate
CAS#78308-49-3 (diacetate hydrate)

Theoretical Analysis

MedKoo Cat#: 575939

Name: Gonadorelin diacetate hydrate

CAS#: 78308-49-3 (diacetate hydrate)

Chemical Formula: C59H91N17O21

Exact Mass: 1373.6575

Molecular Weight: 1374.47

Elemental Analysis: C, 51.56; H, 6.67; N, 17.32; O, 24.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
34973-08-5 (acetate) 33515-09-2 (free base) 51952-41-1 (HCl) 499785-55-6(monoacetate) 78308-49-3 (diacetate hydrate) 71447-49-9 (diacetate)
Synonym
Gonadorelin diacetate hydrate; Luteinizing hormone-releasing factor acetate (salt) hydrate
IUPAC/Chemical Name
diacetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;tetrahydrate
InChi Key
SDNVIIVXSXKODN-KYOBJPNESA-N
InChi Code
InChI=1S/C55H75N17O13.2C2H4O2.4H2O/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36;2*1-2(3)4;;;;/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60);2*1H3,(H,3,4);4*1H2/t36-,37-,38-,39-,40-,41-,42-,43-;;;;;;/m0....../s1
SMILES Code
O=C(CNC([C@H]1N(CCC1)C([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N2)CCC2=O)=O)CC3=CNC=N3)=O)CC4=CNC5=C4C=CC=C5)=O)CO)=O)CC6=CC=C(C=C6)O)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)=O)N.OC(C)=O.OC(C)=O.[H]O[H].[H]O[H].[H]O[H].[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,374.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Li CX, Tang ST, Zhang Q. Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism. Int J Endocrinol. 2015;2015:324524. doi: 10.1155/2015/324524. Epub 2015 Aug 31. PubMed PMID: 26417369; PubMed Central PMCID: PMC4568382. 2: Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1387-9. doi: 10.1515/jpem-2015-0183. PubMed PMID: 26197466. 3: Poock SE, Lamberson WR, Lucy MC. Effect of different gonadorelin (GnRH) products used for the first or resynchronized timed artificial insemination on pregnancy rates in postpartum dairy cows. Theriogenology. 2015 Sep 1;84(4):504-8. doi: 10.1016/j.theriogenology.2015.04.002. Epub 2015 Apr 14. PubMed PMID: 25979657. 4: Picard-Hagen N, Lhermie G, Florentin S, Merle D, Frein P, Gayrard V. Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology. 2015 Jul 15;84(2):177-83. doi: 10.1016/j.theriogenology.2015.03.004. Epub 2015 Mar 14. PubMed PMID: 25890780. 5: Fu JF, Liang JF, Zhou XL, Prasad HC, Jin JH, Dong GP, Rose SR. Impact of BMI on gonadorelin-stimulated LH peak in premenarcheal girls with idiopathic central precocious puberty. Obesity (Silver Spring). 2015 Mar;23(3):637-43. doi: 10.1002/oby.21010. Epub 2015 Feb 3. PubMed PMID: 25645648.

View History

RG3039

RG3039

New Featured